|
12 Sep 2025 |
Cipla
|
Consensus Share Price Target
|
1560.80 |
1676.69 |
- |
7.43 |
buy
|
|
|
|
|
27 Jul 2023
|
Cipla
|
Axis Direct
|
1560.80
|
1250.00
|
1171.45
(33.24%)
|
Target met |
Buy
|
|
|
We have BUY on Cipla
|
|
27 Jul 2023
|
Cipla
|
ICICI Securities Limited
|
1560.80
|
1300.00
|
1068.50
(46.07%)
|
Target met |
Buy
|
|
|
Cipla’s Q1FY24 performance was a beat on all fronts, driven primarily by swift uptick in the core markets of India (up 12%) and US (up ~9% QoQ). gRevlimid continues to be an important product in the US, though traction in Q1 was driven by volume growth in the base portfolio.
|
|
26 Jul 2023
|
Cipla
|
Prabhudas Lilladhar
|
1560.80
|
1220.00
|
1068.50
(46.07%)
|
Target met |
Buy
|
|
|
|
|
17 May 2023
|
Cipla
|
Geojit BNP Paribas
|
1560.80
|
1120.00
|
923.95
(68.93%)
|
Target met |
Buy
|
|
|
|
|
16 May 2023
|
Cipla
|
SMC online
|
1560.80
|
|
922.10
(69.27%)
|
|
Results Update
|
|
|
|
|
15 May 2023
|
Cipla
|
Axis Direct
|
1560.80
|
1100.00
|
922.80
(69.14%)
|
Target met |
Buy
|
|
|
Company Outlook & Guidance: gAdvair and gAbraxane may add revenue in FY25E despite current regulatory challenges. gSynbicort is to be launched in Q4FY24 and the company has planned to launch three more peptides in the next year (size $30-50 Mn).
|
|
13 May 2023
|
Cipla
|
ICICI Direct
|
1560.80
|
1090.00
|
937.45
(66.49%)
|
Target met |
Buy
|
|
|
|
|
13 May 2023
|
Cipla
|
BOB Capital Markets Ltd.
|
1560.80
|
1170.00
|
937.45
(66.49%)
|
Target met |
Buy
|
|
|
Q4 EBITDA/PAT grew 57%/45% YoY but missed consensus by 5%/30% on higher R&D spend, field force expansion and other costs
|
|
01 Mar 2023
|
Cipla
|
Prabhudas Lilladhar
|
1560.80
|
1070.00
|
899.60
(73.50%)
|
Target met |
Buy
|
|
|
|
|
28 Feb 2023
|
Cipla
|
Motilal Oswal
|
1560.80
|
990.00
|
906.40
(72.20%)
|
Target met |
Neutral
|
|
|
|